Navigation Links
Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
Date:11/3/2008

SAN DIEGO, Nov. 3 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical study with MP-376 for use as a maintenance therapy in reducing the incidence of pulmonary exacerbations in patients with chronic obstructive pulmonary disease (COPD). MP-376 is the company's novel formulation of levofloxacin inhalation solution.

The Phase 2, U.S. multi-center randomized, double-blind, placebo-controlled study (Mpex 302) is expected to enroll approximately 300 COPD patients to evaluate the safety, tolerability and efficacy of 5 days of dosing every 28 days, for up to 12 treatment cycles. Inclusion criteria are designed to enroll patients at high risk for acute exacerbations. The primary efficacy endpoint in this study is a comparison of the rate of acute exacerbations in patients treated with MP-376 versus placebo control. Additional endpoints will include the number, duration and severity of acute exacerbations, lung function, quality of life and functional status.

Chronic bacterial infection of the lower airways of patients with COPD results in inflammation that causes lung damage, as well as predisposes patients to acute exacerbations that arise from a variety of causes. Bacterial infections are a leading cause of these exacerbations and antibiotics are widely used to treat exacerbations when they occur. Although several bronchodilators and anti-inflammatory agents have been licensed for maintenance treatment, there are currently no inhaled antibiotics that are cleared for use in the U.S. for preventing the root cause of these exacerbations.

"There is significant enthusiasm in the clinical community for an inhaled antibiotic that can reduce the incidence of acute exacerbations in COPD in high risk patients," stated Dr. Jeff Loutit, Chief Medical Officer of Mpex Pharmaceuticals. "A therapy that addresses the underlying issues associated with COPD to reduce exacerbations would be highly beneficial and potentially result in slowing decline in lung function, improving quality of life, and reducing hospitalizations. We believe aerosol MP-376 is particularly well suited to confer such a benefit and we are eager to work with COPD physicians and patients to assess its potential in this indication."

Levofloxacin, the active ingredient in MP-376, has been shown in clinical studies to be active when given systemically against all of the common pathogens associated with bacterial exacerbations in COPD patients. By delivering the novel MP-376 formulation via the aerosol route, levofloxacin can be delivered directly to the lungs at much higher concentrations than can be achieved through usual oral and intravenous routes of administration. High concentrations are important to maximize bacterial killing and reduce the potential for development of drug resistance. Systemic exposures to levofloxacin are expected to be low when aerosol administration of MP-376 is used, potentially reducing the incidence of systemic side effects. MP-376 is also in clinical trials for potential use as a maintenance treatment in patients with cystic fibrosis.

About COPD

There are more than 9 million patients with COPD in the U.S. Approximately 10% of these patients are characterized as having severe disease which typically results in multiple acute exacerbations per year. These respiratory exacerbations are a major cause of disability, morbidity, mortality and healthcare expenditures. There is no cure for COPD and as such, current treatment is aimed at managing symptoms and preventing exacerbations.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's most advanced product candidate, MP-376, is a proprietary aerosol formulation of levofloxacin that is being developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and COPD. The company has also built a discovery and development platform and intellectual property estate around inhibitors of multi-drug resistant (MDR) efflux pumps (EPIs) found in many gram-negative bacterial pathogens. Bacterial efflux of antibiotics is a leading source of multi-drug resistance, particularly in gram-negative organisms. Mpex compounds have been shown in both in vitro and in vivo studies to overcome efflux-based resistance to multiple classes of antibiotics. Mpex recently entered into a collaboration with GlaxoSmithKline focused on developing multiple drug candidates utilizing Mpex's EPI technology. Company website: http://www.mpexpharma.com.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
5. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
6. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
7. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
8. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... 2017 Obese people are seldom ... varicose veins in their body. The rising number of ... adoption of endovenous laser therapy for treatment of varicose ... therapy market, published by Future Market Insights, indicates ... consequences of obesity have collectively factored the growth in ...
Breaking Medicine Technology:
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated ... National Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual ... Bunkum winner is the Center for American Progress (CAP), for its report, Lessons From ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
Breaking Medicine News(10 mins):